The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
Open accessPublished version of a preprint
Abstract
BACKGROUND: Several cases of unusual thrombotic events and thrombocytopenia have developed after vaccination with the recombinant adenoviral vector encoding the spike protein antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (ChAdOx1 nCov-19, AstraZeneca). More data were needed on the pathogenesis of this unusual clotting disorder. METHODS: We assessed the clinical and laboratory features of 11 patients in Germany and Austria in whom thrombosis or thrombocytopenia had developed after vaccination with ChAdOx1 nCov-19. We used a standard enzyme-linked immunosorbent assay to detect platelet factor 4 (PF4)-heparin antibodies and a modified (PF4-enhanced) platelet-activation test to detect platelet-activating antibodies under various reaction conditions. Included in this testing were samples from patients who had blood samples referred for investigation of vaccine-associated thrombotic events, with 28 testing positive on a screening PF4-heparin immunoassay. RESULTS: Of the 11 original patients, 9 were women, with a median age of 36 years (range, 22 to 49). Beginning 5 to 16 days after vaccination, the patients presented with one or more thrombotic events, with the exception of 1 patient, who presented with fatal intracranial hemorrhage. Of the patients with one or more thrombotic events, 9 had cerebral venous thrombosis, 3 had splanchnic-vein thrombosis, 3 had pulmonary embolism, and 4 had other thromboses; of these patients, 6 died. Five patients had disseminated intravascular coagulation. None of the patients had received heparin before symptom onset. All 28 patients who tested positive for antibodies against PF4-heparin tested positive on the platelet-activation assay in the presence of PF4 independent of heparin. Platelet activation was inhibited by high levels of heparin, Fc receptor-blocking monoclonal antibody, and immune globulin (10 mg per milliliter). Additional studies with PF4 or PF4-heparin affinity purified antibodies in 2 patients confirmed PF4-dependent platelet activation. CONCLUSIONS: Vaccination with ChAdOx1 nCov-19 can result in the rare development of immune thrombotic thrombocytopenia mediated by platelet-activating antibodies against PF4, which clinically mimics autoimmune heparin-induced thrombocytopenia. (Funded by the German Research Foundation.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thrombocytopenia and immune thrombocytopenia (ITP) were also included due to their association with TTS and reports of ITP as an independent safety signal [7,19,20].”
From COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals (2024) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“These adverse events, which primarily affect young women, have been linked with the ChAdOx1 nCoV-1932 and Ad26.COV2.S (Johnson & Johnson–Janssen) Covid-19 vaccines,33 both of which are adenoviral vector vaccines.”
From Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting (2021) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cuker, A. C., Arepally, G. M., Chong, B. H., Cines, D. B., Greinacher, A., Gruel, Y., Linkins, L. A., Rodner, S. B., Selleng, S., Warkentin, T. E., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018024489 · Cited by 755
Self-citationCLINICAL PRACTICE. Heparin-Induced Thrombocytopenia.
Greinacher, A. (2015) · PubMed · doi:10.1056/nejmcp1411910 · Cited by 612
Self-citationDelayed-Onset Heparin-Induced Thrombocytopenia and Thrombosis
Warkentin, T. E., & Kelton, J. G. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-7-200110020-00009 · Cited by 463
Self-citationAutoimmune heparin‐induced thrombocytopenia
Greinacher, A., Selleng, K., & Warkentin, T. E. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13813 · Cited by 414
Self-citationDelayed-Onset Heparin-Induced Thrombocytopenia
Rice, L., Attisha, W. K., Drexler, A. J., & Francis, J. L. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-3-200202050-00009 · Cited by 268
Othman, M., Labelle, A., Mazzetti, I., Elbatarny, H. S., & Lillicrap, D. (2006) · Blood · doi:10.1182/blood-2006-06-032524 · Cited by 220
Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review
Warkentin, T. E., Pai, M., & Linkins, L. (2017) · Blood · doi:10.1182/blood-2017-04-778993 · Cited by 210
Self-citationWarkentin, T. E. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1636645 · Cited by 180
Self-citationA Spontaneous Prothrombotic Disorder Resembling Heparin-induced Thrombocytopenia
Warkentin, T. E., Makris, M., Jay, R. M., & Kelton, J. G. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.03.012 · Cited by 170
Self-citationJuhl, D., Eichler, P., Lübenow, N., Strobel, U., Wessel, A., & Greinacher, A. (2006) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00621.x · Cited by 170
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,001
Fabricius, D., Ludwig, C., Scholz, J. A. M., Rode, I., Tsamadou, C., Jacobsen, E., Winkelmann, M., Grempels, A., Lotfi, R., Janda, A., et al. (2021) · Vaccines · doi:10.3390/vaccines9080918 · Cited by 42
Al-Karmalawy, A. A., Soltane, R., Elmaaty, A. A., Tantawy, M. A., Antar, S. A., Yahya, G., Chrouda, A., Pashameah, R. A., Mustafa, M., Mraheil, M. A., et al. (2021) · Vaccines · doi:10.3390/vaccines9111317 · Cited by 43
Folegatti, P. M., Jenkin, D., Morris, S. J., Gilbert, S. C., Kim, D., Robertson, J. S., Smith, E. R., Martin, E., Gurwith, M., & Chen, R. T. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.06.008 · Cited by 44
Mix-and-Match COVID-19 Vaccinations (Heterologous Boost): A Review
Garg, I., Sheikh, A. B., Pal, S., & Shekhar, R. (2022) · Infectious Disease Reports · doi:10.3390/idr14040057 · Cited by 47
Klemis, V., Schmidt, T., Schub, D., Mihm, J., Marx, S., Abu‐Omar, A., Ziegler, L., Hielscher, F., Guckelmus, C., Urschel, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32321-0 · Cited by 45
Hvidt, A. K., Baerends, E. A. M., Søgaard, O. S., Stærke, N. B., Raben, D., Reekie, J., Nielsen, H., Johansen, I. S., Wiese, L., Benfield, T., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.994160 · Cited by 43
Akache, B., Renner, T. M., Tran, A., Deschatelets, L., Dudani, R., Harrison, B. A., Duque, D., Haukenfrers, J., Rossotti, M. A., Gaudreault, F., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-01363-7 · Cited by 43
Thrombosis and thrombocytopenia after HPV vaccination
Johansen, S., Lægreid, I. J., Ernstsen, S. L., Azrakhsh, N. A., Kittang, A. O., Lindås, R., Gjertsen, B. T., Vetti, N., Mørtberg, T. V., Sørvoll, I. H., et al. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15604 · Cited by 47
van Kammen, M. S., Heldner, M. R., Brodard, J., Scutelnic, A., Silvis, S. M., Schroeder, V., Hovinga, J. A. K., Middeldorp, S., Levi, M. M., Hiltunen, S., et al. (2021) · JAMA · doi:10.1001/jama.2021.9889 · Cited by 43
Gangat, N., Guglielmelli, P., Betti, S., Farrukh, F., Carobbio, A., Barbui, T., Vannucchi, A. M., Stefano, V. D., & Tefferi, A. (2021) · American Journal of Hematology · doi:10.1002/ajh.26336 · Cited by 43
The Coronavirus pandemic – 2022: Viruses, variants & vaccines
Alexandridi, M., Mazej, J., Palermo, E., & Hiscott, J. B. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.02.002 · Cited by 44
Blood Pressure Increase following COVID-19 Vaccination: A Systematic Overview and Meta-Analysis
Angeli, F., Reboldi, G., Trapasso, M., Santilli, G., Zappa, M., & Verdecchia, P. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9050150 · Cited by 47
Neurological Complications Following COVID-19 Vaccination
Chatterjee, A., & Chakravarty, A. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01247-x · Cited by 46
Saha, A., Roy, S. G., Dwivedi, R., Tripathi, P., Kumar, K., Nambiar, S. M., & Pathak, R. (2025) · Vaccines · doi:10.3390/vaccines13040424 · Cited by 47
Marcucci, R., & Marietta, M. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02793-x · Cited by 43
Yayehrad, A. T., Siraj, E. A., Wondie, G. B., Alemie, A. A., Derseh, M. T., & Ambaye, A. S. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s327334 · Cited by 43
Islam, A., Bashir, M. S., Joyce, K. W., Rashid, H., Laher, I., & Elshazly, S. A. (2021) · Molecules · doi:10.3390/molecules26165004 · Cited by 47
Serious complications of COVID-19 vaccines: A mini-review
Fragkou, P. C., & Dimopoulou, D. (2021) · Metabolism Open · doi:10.1016/j.metop.2021.100145 · Cited by 43
Petrovszki, D., Walter, F. R., Vigh, J. P., Kocsis, A. E., Valkai, S., Deli, M. A., & Dér, A. (2022) · Biomedicines · doi:10.3390/biomedicines10010188 · Cited by 43
Pai, M., Chan, B., Stall, N. M., Grill, A. K., Ivers, N. M., Maltsev, A., Miller, K. J., Odutayo, A., Razak, F. A., Schull, M. J., et al. (2021) · doi:10.47326/ocsat.2021.02.17.2.0 · Cited by 43
Coronavirus (COVID-19) Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT)
Aleem, A., & Nadeem, A. J. (2021) · Europe PMC (PubMed Central) · Cited by 42
Sørensen, A. L. T., Rolland, M., Hartmann, J. P., Harboe, Z. B., Roed, C., Jensen, T. Ø., Kolte, L., Fassi, D. E., Hillingsø, J., Radziwon‐Balicka, A., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004904 · Cited by 41
Pawlowski, C., Rincón-Hekking, J., Awasthi, S., Pandey, V., Lenehan, P. J., Venkatakrishnan, A., Bade, S., O’Horo, J. C., Virk, A., Swift, M. D., et al. (2021) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2021.105923 · Cited by 42
Alghamdi, A., Ibrahim, A. A. M., Almutairi, R., Joseph, M. V., Alghamdi, G., & Alhamza, A. (2021) · Journal Of Advanced Pharmacy Education And Research · doi:10.51847/bcwca2qgfp · Cited by 43
Central retinal vein occlusion post-COVID-19 vaccination
Sonawane, N. J., Yadav, D., Kota, A. R., & Singh, H. V. (2021) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1757_21 · Cited by 43
Complement mediates binding and procoagulant effects of ultralarge HIT immune complexes
Khandelwal, S., Barnes, A., Rauova, L., Sarkar, A., Rux, A. H., Yarovoi, S. V., Zaitsev, S. S., Lambris, J. D., Myoung, S. S., Johnson, A., et al. (2021) · Blood · doi:10.1182/blood.2020009487 · Cited by 42
Acute hyperglycaemic crisis after vaccination against COVID‐19: A case series
Edwards, A. E., Vathenen, R., Henson, S. M., Finer, S., & Gunganah, K. (2021) · Diabetic Medicine · doi:10.1111/dme.14631 · Cited by 42
Ahmed, S., Khan, S., Imran, I., Mughairbi, F. A., Sheikh, F. S., Hussain, J., Khan, A., & Al‐Harrasi, A. (2021) · Vaccines · doi:10.3390/vaccines9080836 · Cited by 41
COVID-19 vaccination in patients with immune thrombocytopenia
Visser, C., Swinkels, M., van Werkhoven, E. D., Croles, F. N., Noordzij-Nooteboom, H. S., Eefting, M., Last-Koopmans, S. M., Idink, C., Westerweel, P. E., Santbergen, B., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021006379 · Cited by 41
Safety Monitoring of COVID ‐19 Vaccines: Perspective from the European Medicines Agency
Durand, J., Dogné, J., Cohet, C., Browne, K., Gordillo‐Marañón, M., Piccolo, L., Zaccaria, C., & Genov, G. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2828 · Cited by 41
Cerebral venous thrombosis and thrombocytopenia post-COVID-19 vaccination
Franchini, M., Testa, S., Pezzo, M. P., Glingani, C., Caruso, B., Terenziani, I., Pognani, C., Bellometti, S. A., & Castelli, G. P. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.04.001 · Cited by 41
Ye, X., Ma, T., Blais, J. E., Yan, V. K. C., Kang, W. C. M., Chui, C. S. L., Lai, F. T. T., Li, X., Wan, E. Y. F., Wong, C. K. H., et al. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac068 · Cited by 41
COVID-19 Vaccination in Korea: Past, Present, and the Way Forward
Nham, E., Song, J. Y., Noh, J. Y., Cheong, H. J., & Kim, W. J. (2022) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e351 · Cited by 42
Cerebral Vein Thrombosis With Vaccine-Induced Immune Thrombotic Thrombocytopenia
Siegler, J. E., Klein, P., Yaghi, S. R., Vigilante, N. F., Abdalkader, M. K., Coutinho, J. M., Khalek, F. A., & Nguyen, T. N. (2021) · Stroke · doi:10.1161/strokeaha.121.035613 · Cited by 42
COVID-19 Vaccines and Thrombosis—Roadblock or Dead-End Street?
Lundstrom, K. H., Barh, D., Uhal, B. D., Takayama, K., Aljabali, A. A. A., El‐Aziz, T. M. A., Lal, A., Redwan, E. M. M. M., Adadi, P., Chauhan, G., et al. (2021) · Biomolecules · doi:10.3390/biom11071020 · Cited by 43
Severe autoimmune hemolytic anemia following receipt of SARS‐CoV ‐2 mRNA vaccine
Gadi, S. R. V., Brunker, P. A. R., Al-Samkari, H. T., Sykes, D. B., Saff, R. R., Lo, J., Bendapudi, P. K., Leaf, D. E., & Leaf, R. K. (2021) · Transfusion · doi:10.1111/trf.16672 · Cited by 40
Safety and Efficacy of the Common Vaccines against COVID-19
Liu, Y., & Ye, Q. (2022) · Vaccines · doi:10.3390/vaccines10040513 · Cited by 44
Crisafulli, S., Bate, A., Brown, J. S., Candore, G., Chandler, R. E., Hammad, T. A., Lane, S., Maro, J. C., Norén, G. N., Pariente, A., et al. (2025) · Drug Safety · doi:10.1007/s40264-025-01548-3 · Cited by 40
Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia
Iba, T., Levy, J. H., & Warkentin, T. E. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005211 · Cited by 40
Self-citationGresele, P., Momi, S., Marcucci, R., Ramundo, F., Stefano, V. D., & Tripodi, A. (2021) · Haematologica · doi:10.3324/haematol.2021.279289 · Cited by 41
Singh, A., Toma, F., Uzun, G., Wagner, T. R., Pelzl, L., Zlamal, J., Freytag, V., Weich, K., Nowak‐Harnau, S., Rothbauer, U., et al. (2022) · Blood · doi:10.1182/blood.2021013839 · Cited by 40
Berild, J. D., Larsen, V. B., Thiesson, E. M., Lehtonen, T., Grøsland, M., Helgeland, J., Wolhlfahrt, J., Hansen, J. V., PALMU, A. A. I., & Hviid, A. P. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.17375 · Cited by 39
Vaccines platforms and COVID-19: what you need to know
Acosta-Coley, I., Cervantes-Ceballos, L., Benítez, L. P. T., Sierra-Marquez, L., Cabarcas-Montalvo, M., Espiñeira, M. C. G., Coronell-Rodríguez, W., & Arroyo-Salgado, B. (2022) · Tropical Diseases Travel Medicine and Vaccines · doi:10.1186/s40794-022-00176-4 · Cited by 40
Fondaparinux Sodium: Recent Advances in the Management of Thrombosis
Bauersachs, R. M. (2023) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484221145010 · Cited by 40
COVID-19 Vaccines: Current and Future Perspectives
Soraci, L., Lattanzio, F., Soraci, G., Gambuzza, M. E., Pulvirenti, C., Cozza, A., Corsonello, A., Luciani, F., & Rezza, G. (2022) · Vaccines · doi:10.3390/vaccines10040608 · Cited by 42
Acute Inflammatory Diseases of the Central Nervous System After SARS-CoV-2 Vaccination
Francis, A. G., Elhadd, K. T., Camera, V., dos Santos, M. F., Rocchi, C., Adib‐Samii, P., Athwal, B. S., Attfield, K. E., Barritt, A. W., Craner, M. J., et al. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200063 · Cited by 39
Law, J. L., Logan, M. R., Joyce, M., Landi, A., Hockman, D. J., Crawford, K., Johnson, J., LaChance, G., Saffran, H. A., Shields, J. A., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.081 · Cited by 41
Lessons from vaccine-induced immune thrombotic thrombocytopenia
Kelton, J. G., Arnold, D. M., & Nazy, I. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00642-8 · Cited by 39
Ebeyer-Masotta, M., Eichhorn, T., Weiss, R., Semak, V., Lauková, L., Fischer, M. B., & Weber, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031823 · Cited by 39
Payne, A. B., Adamski, A., Abe, K., Reyes, N., Richardson, L., Hooper, W., & Schieve, L. (2022) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12682 · Cited by 34
Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective
Schwartze, J. T., Havenga, M. J. E., Bakker, W. A. M., Bradshaw, A. C., & Nicklin, S. A. (2022) · Journal of Molecular Medicine · doi:10.1007/s00109-022-02208-0 · Cited by 42
Four cases of cytokine storm after COVID-19 vaccination: Case report
Murata, K., Nakao, N., Ishiuchi, N., Fukui, T., Katsuya, N., Fukumoto, W., Oka, H., Yoshikawa, N., Nagao, T., Namera, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.967226 · Cited by 39
Malik, B. H., Kalantary, A., Rikabi, K., & Kunadi, A. R. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-243975 · Cited by 38
Chen, P.-W., Tsai, Z.-Y., Chao, T.-H., Li, Y.-H., Hou, C. J., & Liu, P.-Y. (2021) · PubMed Central · doi:10.6515/acs.202107_37(4).20210628a · Cited by 39
Wiedmann, M. K. H., Skattør, T. H., Stray‐Pedersen, A., Romundstad, L. G., Antal, E., Marthinsen, P. B., Sørvoll, I. H., Ernstsen, S. L., Lund, C. G., Holme, P. A., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.721146 · Cited by 38
COVID-19 Immunobiology: Lessons Learned, New Questions Arise
Kaklamanos, A., Belogiannis, K., Skendros, P., Gorgoulis, V. G., Vlachoyiannopoulos, P. G., & Tzioufas, A. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.719023 · Cited by 37
Fragoso, Y. D., Gomes, S., Gonçalves, M. V. M., Júnior, E. M., de Oliveira, B. E. S., Rocha, C. F., dos Santos, G. A. C., Tauil, C. B., Araujo, R. V., & Peron, J. P. S. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103321 · Cited by 38
RetractedSunagar, R., Prasad, S. D., Ella, R., & Vadrevu, K. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1063679 · Cited by 38
Circulating SARS-CoV-2+ megakaryocytes are associated with severe viral infection in COVID-19
Fortmann, S. D., Patton, M. J., Frey, B. F., Tipper, J. L., Reddy, S. B., Vieira, C. P., Hanumanthu, V. S., Sterrett, S., Floyd, J. L., Prasad, R., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009022 · Cited by 38
Cittone, M. G., Battegay, R., Condoluci, A., di Bergamo, L. T., Fernandes, E., Galfetti, E., Noseda, R., Leuppi-Taegtmeyer, A. B., Drexler, B., Ceschi, A., et al. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15421 · Cited by 38
Acute myocarditis following administration of BNT162b2 vaccine
Habib, M. B., Hamamyh, T., Elyas, A. A., Altermanini, M., & Elhassan, M. (2021) · IDCases · doi:10.1016/j.idcr.2021.e01197 · Cited by 37
COVID-19 mRNA vaccine induced rhabdomyolysis and fasciitis
Faissner, S., Richter, D., Ceylan, U., Schneider‐Gold, C., & Gold, R. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10768-3 · Cited by 37
The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2
Ho, T., Chen, Y. A., Chan, H.-P., Chang, C.-C., Chuang, K., Lee, C., Yuan, C., Tyan, Y., & Yang, M. (2021) · Vaccines · doi:10.3390/vaccines9101163 · Cited by 40
COVID-19 Coagulopathy: From Pathogenesis to Treatment
Alnima, T., Mulder, M. M. G., van Bussel, B. C. T., & Cate, H. T. (2022) · Acta Haematologica · doi:10.1159/000522498 · Cited by 38
Immune Response to SARS-CoV-2 Vaccines
Bellamkonda, N., Lambe, U. P., Sawant, S. A., Nandi, S. S., Chakraborty, C., & Shukla, D. (2022) · Biomedicines · doi:10.3390/biomedicines10071464 · Cited by 37
Risk assessment of retinal vascular occlusion after COVID-19 vaccination
Li, J., Wang, Y., Bair, H., Hsu, S., Chen, C., Wei, J. C., & Lin, C. (2023) · npj Vaccines · doi:10.1038/s41541-023-00661-7 · Cited by 37
Lee, S., Sankhala, K. K., Bose, S., & Gallemore, R. P. (2022) · International Medical Case Reports Journal · doi:10.2147/imcrj.s328931 · Cited by 37
Cerebral Venous Sinus Thrombosis Following COVID-19 Vaccination: A Systematic Review
Jaiswal, V., Nepal, G., Dijamco, P., Ishak, A., Dagar, M., Sarfraz, Z., Shama, N., Sarfraz, A., Lnu, K., Mitra, S., et al. (2022) · Journal of Primary Care & Community Health · doi:10.1177/21501319221074450 · Cited by 37
Natural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis
Craven, B., Lester, W., Boyce, S., Thomas, W., Kanny, A., Davies, C. R., Pavord, S. R., Hermans, J., Makris, M., Bart‐Smith, E., et al. (2022) · Blood · doi:10.1182/blood.2021014684 · Cited by 37
Gisby, J., Buang, N. B., Papadaki, A., Clarke, C., Malik, T. H., Medjeral‐Thomas, N., Pinheiro, D., Mortimer, P. M., Lewis, S., Sandhu, E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35454-4 · Cited by 39
Cerebral venous sinus thrombosis 2 weeks after the first dose of mRNA SARS-CoV-2 vaccine
Zakaria, Z., Sapiai, N. A., & Ghani, A. R. I. (2021) · Acta Neurochirurgica · doi:10.1007/s00701-021-04860-w · Cited by 36
Inflammatory myositis after ChAdOx1 vaccination
Maramattom, B. V., Philips, G., Thomas, J., & Santhamma, S. G. N. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00312-x · Cited by 36
Koh, J. S., Hoe, R. H. M., Yong, M. H., Chiew, H. J., Goh, Y., Yong, K. P., Tu, T. M., Chan, D. W. S., Tan, B. Y., Yeo, L. L. L., et al. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120030 · Cited by 36
Complicated Long Term Vaccine Induced Thrombotic Immune Thrombocytopenia—A Case Report
Günther, A., Brämer, D., Pletz, M. W., Kamradt, T., Baumgart, S., Mayer, T. E., Baier, M., Autsch, A., Mawrin, C., Schönborn, L., et al. (2021) · Vaccines · doi:10.3390/vaccines9111344 · Cited by 36
Self-citationClinical Application of Adenovirus (AdV): A Comprehensive Review
Salauddin, M., Saha, S., Hossain, M. G., Okuda, K., & Shimada, M. (2024) · Viruses · doi:10.3390/v16071094 · Cited by 43
Lin, Y., Yen, C., Chang, Y., & Wang, P. (2021) · Vaccines · doi:10.3390/vaccines9050528 · Cited by 36
Reid, J. A., & Mabhala, M. A. (2021) · Israel Journal of Health Policy Research · doi:10.1186/s13584-021-00467-9 · Cited by 36
The pathological maelstrom of COVID-19 and cardiovascular disease
Giacca, M., & Shah, A. M. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00029-5 · Cited by 37
Syrmou, V., Liaskos, C., Ntavari, N., Mitsimponas, K. T., Simopoulou, T., Alexiou, I., Vlychou, M., Katsiari, C. G., & Bogdanos, D. P. (2023) · Immunologic Research · doi:10.1007/s12026-023-09368-2 · Cited by 36
Trogstad, L., Robertson, A. H., Mjaaland, S., & Magnus, P. M. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.055 · Cited by 35
Gupta, A. A., Sardar, P., Cash, M. E., Milani, R. V., & Lavie, C. J. (2021) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2021.05.001 · Cited by 35
Mazzatenta, C., Piccolo, V., Pace, G., Romano, I. J., Argenziano, G., & Bassi, A. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17340 · Cited by 35
COVID-19 vaccines and thrombosis with thrombocytopenia syndrome
Lai, C., Ko, W., Chen, C., Chen, P.-Y., Huang, Y., Lee, P., & Hsueh, P. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1949294 · Cited by 39
Antibody Fingerprints Linking Adenoviral Anti-PF4 Disorders
Wang, J. J., Schönborn, L., Warkentin, T. E., Chataway, T., Grosse, L., Simioni, P., Moll, S., Greinacher, A., & Gordon, T. P. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2402592 · Cited by 35
Self-citationHodel, K. V. S., Fiuza, B. S. D., Conceição, R. S., Aleluia, A. C. M., Pitanga, T. N., Fonseca, L. M. D. S., Valente, C. O., Rezende, C. S. M. E., & Machado, B. A. S. (2024) · Pharmaceuticals · doi:10.3390/ph17060807 · Cited by 38
Chen, V. M. Y., Curnow, J. L., Tran, H. A., & Choi, P. (2021) · The Medical Journal of Australia · doi:10.5694/mja2.51229 · Cited by 35
Uzun, G., Pelzl, L., Singh, A., & Bakchoul, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.837629 · Cited by 35
Recommendations from the ICM-VTE: General
Delegates, T. I.-V. G. (2022) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.21.01531 · Cited by 36
Tu, T. M., Shen, J. Y., Koh, J. S., Saffari, S. E., Hoe, R. H. M., Chen, G. J., Chiew, H. J., Tham, C. H., Seet, C. Y. H., Yong, M. H., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.2940 · Cited by 35
Wan, E. Y. F., Wang, Y., Chui, C. S. L., Mok, A. H. Y., Xu, W., Yan, V. K. C., Lai, F. T. T., Li, X., Wong, C. K. H., Chan, E. W., et al. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(22)00125-8 · Cited by 36
Warkentin, T. E., Arnold, D. M., Sheppard, J. I., Moore, J. C., Kelton, J. G., & Nazy, I. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.04.034 · Cited by 37
Self-citationAdenovirus-Vectored COVID-19 Vaccine–Induced Immune Thrombosis of Carotid Artery
Walter, U., Fuchs, M., Großmann, A., Walter, M., Thiele, T., Storch, A., & Wittstock, M. (2021) · Neurology · doi:10.1212/wnl.0000000000012576 · Cited by 34
Self-citationInformation systems for vaccine safety surveillance
Buttery, J. P., & Clothier, H. J. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2100173 · Cited by 34
Cardiovascular complications of COVID-19 vaccines: A review of case-report and case-series studies
Paknahad, M. H., Yancheshmeh, F. B., & Soleimani, A. (2023) · Heart & Lung · doi:10.1016/j.hrtlng.2023.02.003 · Cited by 34
Chiappalupi, S., Salvadori, L., Donato, R., Riuzzi, F., & Sorci, G. (2021) · Biomolecules · doi:10.3390/biom11060876 · Cited by 35
Antiplatelet drugs block platelet activation by VITT patient serum
Smith, C. W., Montague, S. J., Kardeby, C., Di, Y., Lowe, G., Lester, W., Watson, S. P., & Nicolson, P. L. R. (2021) · Blood · doi:10.1182/blood.2021012277 · Cited by 36
COVID-19: Update on Its Ocular Involvements, and Complications From Its Treatments and Vaccinations
Lin, T. P. H., Ko, C.-N., Zheng, K., Lai, K. H. W., Wong, R. L. M., Lee, A., Zhang, S., Huang, S. S., Wan, K. H., & Lam, D. S. C. (2021) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000453 · Cited by 37
Favaloro, E. J., Pasalic, L., & Lippi, G. (2022) · Antibodies · doi:10.3390/antib11010007 · Cited by 34
The Underestimated Role of Platelets in Severe Infection a Narrative Review
Fogagnolo, A., Campo, G. C., Mari, M., Pompei, G., Pavasini, R., Volta, C. A., & Spadaro, S. (2022) · Cells · doi:10.3390/cells11030424 · Cited by 34
Metadata
- Authors
- Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S.
- Affiliations
- Universitätsmedizin Greifswald (DE)
- Corresponding author
- Greinacher, Andreas
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-06-03
- Volume
- 384
- Issue
- 22
- Pages
- 2092-2101
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8095372
- OpenAlex
- W3140226555
- Cited by
- 2,259
- References
- 27
- Citations by year
- 2026: 77 · 2025: 139 · 2024: 171 · 2023: 297 · 2022: 725 · 2021: 848
- FWCI
- 479.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (Projektnummer 374031971 – TRR 240)
- Topics
- Health Sciences › Medicine › Hematology › Heparin-Induced Thrombocytopenia and Thrombosis
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- ChAdOx1 nCoV-19 vaccine, AstraZeneca COVID-19 vaccine, vaccine-associated thrombosis, platelet factor 4, PF4/heparin antibodies, platelet-activating antibodies, cerebral venous thrombosis, pulmonary embolism, splanchnic vein thrombosis, disseminated intravascular coagulation, heparin, Fc receptor blockade, gamma globulin
- MeSH terms
- COVID-19 Vaccines, ChAdOx1 nCoV-19, Adult, Autoantibodies, Autoimmune Diseases, Blood Chemical Analysis, Disseminated Intravascular Coagulation, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Platelet Factor 4, Thrombocytopenia, Thrombosis, Platelet Activation, Fatal Outcome, Intracranial Hemorrhages, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
